01:58 am – Wednesday 18 March 2020
Zhang Xinmin, director of the Chinese National Center for Biotechnology Development under the Ministry of Science and Technology, said that “faviravir” – the flu drug – which was approved for clinical use in Japan in 2014, showed no clear negative reactions in the clinical trial, but rather made its recipient Less responsive to HIV chances.
More than 80 patients participated in the clinical trial at the Third People’s Hospital in Shenzhen, south Chinas Guangdong Province, including 35 patients who took faviravir and 45 patients in a control group.
The results showed that patients receiving faviravir treatment became passive to the virus in a shorter time compared to patients in the control group, Xinhua reported.
A randomized, multicenter clinical study conducted by Zhongnan Hospital of Wuhan University revealed that the therapeutic effect of Favipiravir was much better than that of the control group.
Zhang said: The faviravir should be included in the diagnosis and treatment plan for COVID-19 as soon as possible.
Zhang added that the Chinese Medical Products Administration had agreed to a Chinese pharmaceutical company to mass-produce the drug and ensure stable supply.